Optimization strategies for DNA vaccines

Intervirology

Volumn 43, Issue 4-6, 2000, Pages 218-226

  Weeratna, Risini D ^a   Mccluskie, Michael J ^a   Comanita, Lacrimiora ^a   Wu, Tong ^a   Davis, Heather L ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PFIZER INC   (United States)

Author keywords

Antibodies; CpG motifs; Cytotoxic T lymphocytes; DNA vaccines; Immunization strategies, prime boost; Mucosal; Vaccines

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; PLASMID DNA;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HOST CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHROMIUM; CPG ISLANDS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

ANIMALIA;

EID: 0034468127     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053989     Document Type: Article

References (84)

1. Cellular cytotoxic response induced by DNA vaccination of HIV-1-infected patients
2. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
3. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
4. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
5. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
6. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2
7. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens
8. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
9. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants
10. IL-12 gene is a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge
11. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines
12. Cytokines and costimulatory molecules as genetic adjuvants
13. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes
14. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo
15. Cationic lipids enhance cyto-kine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes
16. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1
17. Lipo-some-mediated DNA vaccination
18. Cationic microparticles: A potent delivery system for DNA vaccines
19. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) micro-spheres as a novel approach for immunogene delivery
20. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles
21. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
22. Mucosal and systemic immunization using cochleate and liposome vaccines
23. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes
24. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
25. In vivo priming by DNA injection occurs predominantly by antigen transfer
26. The effect of interferon-gamma on genetic immunization
27. Dendritic cells in genetic immunization
28. DNA immunization targeting the skin: Molecular control of adaptive immunity
29. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization
30. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
31. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate
32. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
33. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization
34. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
35. Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin
36. Mucosal immunization with DNA encoding influenza hemag-glutinin
37. Monophos-phoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
38. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
39. CpG islands as gene markers in the vertebrate nucleus
40. The influence of base sequence on the immunostimulatory properties of DNA
41. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA
42. Induction of natural killer activity in murine and human cells by CpG motifs in oligodeoxynu-cleotides and bacterial DNA
43. Bacterial DNA induces NK cells to produce interferon-γ in vivo and increases the toxicity of lipopolysaccharides
44. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α
45. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-96, IL-12 and IFN-g
46. CpG motifs as immune adjuvants
47. CpG DNA: A novel immunomodulator
48. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
49. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
50. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides
51. Novel strategies using DNA for the induction of mucosal immunity
52. DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody
53. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
54. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
55. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naive and infection-primed mice
56. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun
57. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
58. Induction of genital immunity by DNA priming and intra-nasal booster immunization with a replication-defective adenoviral recombinant
59. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
60. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
61. CpG DNA as mucosal adjuvant
62. Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization
63. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery
64. Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella entericaserovar typhimurium-based DNA vaccine delivery systems
65. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
66. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
67. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen
68. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
69. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
70. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
71. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models
72. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
73. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
74. New vaccine strategies against enterotoxigenic Escherichia coli II. Enhanced systemic and secreted antibody responses against the CFA/I fimbriae by priming with DNA and boosting with a live recombinant Salmonella vaccine
75. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
76. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates
77. Nucleic acid vaccination with HIV regulatory genes: A combination of HIV-1 genes in separate plasmids induces strong immune responses
78. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA
79. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus
80. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene
81. Immunization of the female genital tract with a DNA-based vaccine
82. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees
83. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site
84. Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines